Pharmacogenomics: the Future of Drug Development of Patient care

Mrs. Sandhya S.Ahire[1], Mr. Sujeetkumar I. Ahire, Miss. Prachi Chaudhari[2], Mr. Chetan Chaudhari[2]

[1]*Assistant Prof. &* [2]*Students of KYDSCT College of pharmacy, Sakegaon, Bhusawal. MH.425201*

Abstract: **This study investigates the possible effects of pharmacogenomics, a quickly emerging field that examines the use of genomic markers to forecast how a medicine will be treated. Research on the genetic components that influence individual variations in drug response is part of the rapidly evolving field of pharmacogenomics. A substantial pharmacogenomics knowledge gap in the healthcare workforce and the shift in current therapeutic pathways are two major implementation issues that still arise at the point of delivery into health-care systems. Pharmacogenomics may find wider application in drug research and development as evidence mounts that targets with a genetic definition have a higher success rate throughout clinical development. Pharmaceutical prescribing and dosage can now be done in a particular way thanks to Research on the genetic basis of diversity in medication response has enabled a particular approach to pharmaceutical prescribing and dosing. Here, we address the current status of the field, strategies for addressing some unresolved problems, and the application of pharmacogenomics to guide medication therapy through genetic testing. Future pharmaceutical development may be significantly impacted by pharmacogenomics. This tactic can lessen side effects, halt ineffective treatments, and enhance patients' overall health. As pharmacogenomics data becomes more accessible and incorporated into clinical practice, it has the potential to change the way healthcare is delivered, improving patient satisfaction and results.**

Key words: **clinical practice, pharmacogenetics, pharmacogenes, clinical practice.**

INTRODUCTION TO PHARMACOGENOMICS

Definition & significance of pharmacogeneomics
Pharmacogenomics is the study of the role of the genome in drug response. Its name (*pharmaco-+ genomics*) reflects its combining of pharmacology and genomics.

The study of how the genome affects drug response is known as pharmacogenomics. Its combination of pharmacology and genetics is reflected in its name (pharmaco-+ genomics).

Pharmacogenomics examines how a patient's genetic composition influences how they react to medications.
By linking DNA mutations (such as single-nucleotide polymorphisms, copy number variations, and insertions/deletions) with pharmacokinetics (drug absorption, distribution, metabolism, and elimination), it addresses the impact of inherited and acquired genetic variation on drug response. Immunogenic endpoints and/or pharmacodynamics (effects mediated through a drug's biological targets).

Pharmacogenomics seeks to create logical ways to tailor medication regimens based on a patient's genotype in order to maximize effectiveness and minimize side effects. By removing the need for trial-and-error in prescription, pharmacogenomics enables doctors to evaluate a patient's genes, how those genes operate, and how this may impact the effectiveness of the patient's present or future treatments.

Pharmacogenomics is the study of individual medication reactions using genomic information. It may be possible to make genetically based clinical decisions, such as changing the drug or dose, when a patient's gene variant is linked to a specific medicine response. Researchers evaluate gene variants that impact a person's treatment response in the same manner as they evaluate gene variants linked to illnesses.

Through evaluating people whose response is uncertain after finding genetic loci linked to known drug responses. Whole-genome single nucleotide polymorphism (SNP) profiles and multigene analysis are examples of contemporary methods that are only now beginning to be used in clinical settings for medication development and discovery.

Precision medicine and even customized medicine, where medications and treatment combinations are tailored for certain patient subgroups or even for each

person's distinct genetic composition, are anticipated as a result of such approaches.

It aims to improve treatment outcomes and efficacy, as well as lower drug toxicities and adverse drug reactions (ADRs), whether it is utilized as a predictive tool or to explain a patient's response—or lack thereof—to a treatment.


Figure 1: Benefits of Pharmacogenomics

- Comparing pharmacogenomics and pharmacogenetics:

Pharmacogenetics and pharmacogenomics are frequently used interchangeably. Despite the fact that both phrases refer to pharmacological response influenced by genetics.

Pharmacogenomics tackles the impact of several genes or even chromosomes on drug response using a more genome-wide association approach that combines genomics and epigenetics.

Pharmacogenomics examines how genetic variations in drug metabolism (as well as other pharmacological concepts, such as enzymes, messengers, and receptors) can influence a person's reaction to a drug, both positively and negatively.

Precision medicine includes the field of pharmacogenomics. This is a customized course of treatment based on your lifestyle, surroundings, and genes. Pharmacogenomics can assist your doctor in prescribing a drug that has fewer adverse effects or that might function better for you.

The cells in your body receive instructions from your genes.

Gene's aid in the synthesis of protein molecules called. Among the many other things that enzymes perform is break down drugs. Genetic variations that alter the amount of enzyme produced or its functionality may be the cause of people who don't react to drugs as prescribed.

To better understand how to use a drug on a particular patient or community, pharmacogenetics, on the other hand, concentrates on single drug-gene interactions by taking into account dominance, gene polymorphism, and count allele genes.

The field of pharmacogenetics, which was thought to revolutionize pharmacotherapy, converts genetic variability data into predictions about the pharmacokinetics (PK) and pharmacodynamics (PD) effects of medications.

Patients would no longer be treated with normal pharmaceuticals in a typical dose but, rather, the optimal treatment in the correct dose would be picked for each individual based on a genetic test. In addition, people who were prone to encounter adverse effects would be identified before pharmacological therapy. Regretfully, this forecast has not come to pass.

The study of pharmacological reaction and how it is altered by genetic influences is known as pharmacogenetics. Both toxicity (the creation of undesirable side effects) and efficacy (therapeutic effectiveness) are relevant outcomes. Pharmacogenetics' historical roots can be traced back to reports of serious adverse effects associated with the use of Primaquine, isoniazid, and succinylcholine.


Figure 2 pharmacogenomics & pharmacogenetics study

Genetics advanced quickly after Hugo de Vries, Carl Correns, and Erich von Tschermak rediscover Mendel's work in 1900. By 1915, the fruit fly Drosophila melanogaster was the most notable creature in which the fundamentals of Mendelian genetics had been examined.

Thomas Hunt Morgan and his fellow "drosophilists" led geneticists in the development of the Mendelian model, which by 1925 had gained widespread acceptance. Mathematicians introduced genetic explanations into the study of evolution by developing the statistical framework of population genetics in conjunction with experimental studies.

After establishing the fundamental patterns of genetic inheritance, many biologists focused on studying the physical characteristics of genes. Experiments conducted in the 1940s and early 1950s suggested that DNA was the part of chromosomes (and possibly other nucleoproteins) that contained genes.

The age of molecular genetics began in 1953 with the discovery of the double helical structure of DNA and an emphasis on novel model species like bacteria and viruses. In the years that followed, scientists created methods for sequencing proteins and nucleic acids, and numerous others deduced the genetic code and the connection between these two types of biological components.

In the 1960s, controlling gene expression emerged as a major concern; by the 1970s, genetic engineering had made it possible to control and modify gene expression. Many biologists concentrated on large-scale genetics initiatives in the final decades of the 20th century, such sequencing complete genomes.

- Genomic advancements and their effects on medications:

Genetic technology advancements are significantly influencing clinical practice and requiring a shift in many people's views regarding the function and extent of genetic testing.

There is a greater possibility of diagnosis or future diagnostic predictions with genomic testing, but there is also a greater chance of unclear or unexpected results, many of which could affect several family members.

Genetic testing used to be rarely able to produce results quickly, but as genomic testing becomes more accessible and faster, this is changing, and as a result, genomic data is increasingly affecting decisions about patient treatment in acute inpatient settings.

Treatment options for hereditary illnesses are changing, which has changing consequences for clinical conversations about problems that were previously incurable.


Figure 3: Genomics & clinical data

- What effects is pharmacogenomics having on medical care?

A customized and individualized approach to drug therapy may be possible because to pharmacogenetics (PGx) testing, which provides information on a patient's risk of experiencing both a therapeutic and an unfavorable reaction to a medicine.

It has been estimated that between 20 and 95 percent of the difference in how each person reacts to drugs can be attributed to genetic variation.

Pharmacogenomics technology advancements will guarantee personalized medicine's clinical implementation.

The development of novel biomarkers and the genetic connection of diseases must be accelerated by genomics, transcriptomics, proteomics, metabolomics, and neuroimaging. At the moment, doctors prescribe medications primarily based on a patient's age, weight, sex, and liver and kidney function.

Scientists have discovered gene variations that impact the way people react to certain medications.

In these situations, physicians are able to choose the ideal drug and dosage for every patient.


Figure 4: role of pharmacogenomics in drug development

- Fundamentals of pharmacogenomics

Recent sequencing efforts have identified numerous uncommon genetic variants in genes encoding proteins implicated in drug metabolism, transport, and response, in addition to common genetic polymorphisms.

Genetic variation in phase I and phase II enzymes, transporters, cytochrome reductases, and nuclear receptors—collectively referred to as pharmacogenes—can impact drug absorption, distribution, metabolism, and excretion (ADME), which in turn can impact adverse event risk and human drug response.

- Pharmacogenomics' key genes and genetic markers

Understanding and responding to specific medications depends on key genes and genetic markers. These enzymes digest a wide variety of medicines.

Pharmacogenomics basics: Genetic variation and how it affects drug response
Inconsistent drug reactions can also be caused by variations in a single gene that are unrelated to drug metabolism.

These might be modifications to genes that encode target molecules or pathways that interact with drugs, or they might be modifications to genes that encode genes that have nothing to do with the therapeutic effect.

Gene variations linked to pharmacokinetics or medication response may affect the efficacy of treatment or raise the possibility of adverse drug reactions.

- Pharmacogenomics' key genes and genetic markers

Understanding and responding to specific medications depends on key genes and genetic markers. These enzymes metabolize a wide range of medicines. Variations in the CYP2D6, CYP2C9, and CYP3A4 genes can significantly impact an individual's rate of medication metabolism, which can impact the efficacy of the drug and its potential adverse effects. Human leukocyte antigen (HLA) genes, including HLA-B, are important in predicting hypersensitive reactions to specific drugs.
For example, a higher risk of HLA-B is associated with a severe hypersensitive reaction to the antiretroviral drug abacavir. The UGT1A1 gene metabolizes medications such as irinotecan, which is used to treat cancer.Variations in this gene could affect a person's ability to get rid of the drug from their body. By changing how the body metabolizes the chemotherapeutic medication fluorouracil (5-FU), variations in the DPYD gene may increase the risk of severe toxicity.

Thiopurine S-methyltransferase (TPMT) facilitates the metabolism of thiopurine drugs, including azathioprine and mercaptopurine. Genetic differences in TPMT can lead to changes in drug metabolism and the possibility of harmful side effects.

VKORC1 and CYP2C9 are associated with the side effects of the commonly prescribed anticoagulant warfarin.Variations in these genes may affect a person's sensitivity to warfarin, requiring careful dose adjustments.

The transport of SLCO1B1 is linked to statin drugs, which lower cholesterol levels. Certain variations of SLCO1B1 are associated with an increased risk of statin-induced myopathy. ABCB1 encodes the P-

glycoprotein, which is involved in drug transport and may affect the bioavailability of many medications.

Catechol-O-methyltransferase (COMT) mediates the metabolism of catecholamines and drugs that affect these neurotransmitters. The crucial genes and genomic These are only a few examples of the markers that are the focus of pharmacogenomics research. A greater understanding of a patient's genetic profile in connection to these genes and markers can help health care providers make safer and more informed drug choices and administration decisions. Pharmacogenomic testing, which enables personalized drug therapy based on an individual's genetic composition, is advancing personalized medicine.

• Pharmacokinetic and pharmacodynamics effects

Current definitions of pharmacokinetics and pharmacodynamics include the study of drug absorption, distribution, metabolism, and excretion over time. Clinical pharmacokinetics is the application of pharmacokinetic concepts to the safe and effective therapeutic management of drugs in a single patient.

Despite the fact that drug pharmacokinetics are often subpar, some drugs may show notable variations. The study of pharmacodynamics examines the connection between a drug's concentration at the site of action and the resulting effect, including the length of time and intensity of both positive and negative effects.

When a drug is present at the site of action, its effect is determined by its capacity to bind to a receptor. Receptors can be found on the heart muscle to alter the power of contraction, on neurons in the central nervous system (opiate receptors), or even inside bacteria to disrupt the maintenance of the bacterial cell wall.

There may be sex-related differences in phase I (cytochrome P450) and phase II (especially glucuronidation) responses. Information about the effects of estrogens and progestogens on other drugs and the extent to which they may decrease the effectiveness of contraceptives should be made public, considering the large number of women who use oral contraceptives worldwide.

Furthermore, estrogens interact with a range of enzymes and receptors, including those at dopaminergic receptor sites and endothelial function, to either boost or diminish the effects of drugs, including side effects.

While it is well established that women are more likely than males to have certain drug side effects, it is sometimes unclear whether this is due to gender variations in the pharmacokinetics or pharmacodynamics of the offending medication. Information about these gender-related differences and the possibility that women may react differently to therapies than males is lacking. Drug licensing authorities are increasingly requiring the pharmacokinetics of novel drugs in women as well as a sufficient number of women in effectiveness and outcome trials.

• Importance Of Personalized medicine

Despite the significant advances in drug therapy, some patients still have severe side effects or may not respond adequately to medicines. Pharmacogenetics studies have connected varying drug response to polymorphisms of drug-metabolizing enzymes, transporters, and receptors.

Because pharmacological activities are complex, a more thorough genomics approach aims to maximize treatment for each patient and find new therapeutic targets. However, pharmacogenomics has not yet significantly changed clinical practice.

Among these are the complex ways that treatment response, either alone or in combination, is influenced by the genetic underpinnings of complex diseases including diabetes, cancer, heart disease, and psychiatric the uncertainty surrounding the diseases and the difficulty in measuring the variety of genetic changes, even in well-studied genes.

Pharmacogenomics will lead to significant, albeit slow, therapeutic breakthroughs through the removal of these barriers, which will pave the way for personalized healthcare.

• Pharmacogenomics in drug development

A. Optimizing drug discovery through genomics

Modern drug discovery and development techniques are highly technologically sophisticated and highly

effective. At the same time, compound failure rates are high in both preclinical and clinical development. Research on the composition and operation of the human and animal genomes has transformed biology and medicine throughout the last ten years.

Genes linked to disease may now be identified thanks to human genetics, and methods for sequencing complete genomes and characterizing an organism's gene expression profile in its entirety in a single experiment have been created.

B. Regulatory consideration and FDA guidelines

Not all LDTs are currently regulated by the FDA. For instance, the FDA has chosen not to regulate rare disease tests in order to exercise its enforcement discretion. Additionally, it has not concentrated on chromosomal copy number or genotype determinations.

The FDA did, however, propose in 2006 to broaden its regulatory purview to include a subset of LDTs. In vitro diagnostic tests that combine the values of several variables and use an interpretive function to produce a single, patient-specific result—which could be a classification, score, or index—that is meant to be used in the diagnosis or treatment of a disease but whose derivation is opaque and cannot be independently derived or verified by the treating physician are the ones that the FDA proposed to regulate.

Many of these are designed for pharmacogenomics applications and are referred to as "in vitro multivariate index assays," or "IVDMIAs" for short. The clinical laboratory community has opposed the FDA's efforts due to uncertainty regarding the extent of the agency's strategy, worries that it could result in additional LDT types being regulated by the FDA, and a general increase in clinical laboratory regulation by both the FDA and CMS.

The FDA's draft IVDMIA advice is based on the fundamental idea that the agency should supervise tests that do not allow a doctor to dissect the test and ascertain its actual significance for a given patient. Accordingly, an IVDMIA is a test that evaluates several factors to produce a single figure that corresponds to the patient's course of treatment.

For instance, an IVDMIA may state, "Your patient scores a 5," following the analysis of several SNPs and the use of the test methodology. You would then look up the meaning of number 5, and find out that patients with scores from 1–10 are likely to have recurrent colon cancer while patients with scores from 20 and up do not. Or that individuals with scores between 1 and 10 ought to have chemotherapy, while those with higher scores shouldn't

According to the FDA, the doctor must accept the test result and its meaning in good faith because they are unable to reverse engineer the test. Instead of leaving doctors in the dark, the FDA suggested that it examine and assess the test system's clinical and analytical validity.

- Clinical Implementation of Pharmacogenomics
- o By facilitating personalized medicine, the use of pharmacogenomics (PGx) in clinical settings improves treatment efficacy, safety, and cost-effectiveness.
- o Clinical Implementation Strategy

- Stage 1: Prior to implementation: Research and data synthesis are done to prepare the institution for the initial implementation.
- Stage 2: The developmental phase, in which all of the data that has been gathered and examined is used to construct the institution's workflow model, IT infrastructure, and laboratory operations.
- Stage 3: Implementation and usage of the clinical process model, during which the model is used in the clinic and any issues identified are further fixed. PHR stands for personal health record.

- Role of Pharmacogenomics in Patient Stratification

A key component of our healthcare system is pharmacogenomics. The rapidly developing fields of stratified health care and pharmacogenomics enable healthcare professionals to tailor the "right treatment, for the right person, at the right time."

Patient classification based on effectiveness and disease susceptibility It has been shown that a variety of hereditary traits can predict a drug's success. The therapeutic efficacy of the drug may be jeopardized if certain genetic variants found in these prognostic markers affect the presence or recognition of target receptors or transporter proteins.

Pharmacogenomics plays a crucial role in patient stratification, which is the process of dividing

patients into smaller groups based on characteristics of the disease, genetic makeup, or other criteria.

More efficiency and customization are made possible via stratification. Pharmacogenomics studies how single nucleotide polymorphisms (SNPs) and other genetic variations affect the efficacy, safety, and metabolism of medications.

By identifying distinct genetic variations connected to drug response, pharmacogenomics can help predict a patient's likely response to a particular treatment. This information can be used to tailor treatment plans for individual individuals.

There are genetic variations that can make a person more susceptible to adverse drug reactions. Pharmacogenomics testing can help doctors identify these patients, choose safer treatment choices, or adjust medication dosages because they are deemed to be at-risk.

By understanding their patients' genetic profiles, doctors can select medications and dosages that have a higher chance of being both safe and effective. Because it assists in pinpointing the exact genetic abnormalities that drive the development of cancer, pharmacogenomics is very important in oncology.

Targeted medicines that aim to address these mutations are administered to the appropriate patients thanks to genetic patient stratification.

Pharmacogenomics can reduce the amount of trial and error by guiding treatment decisions from the beginning.

By assisting clinicians in identifying genetic factors that influence medication response, improving treatment plans, improving patient outcomes, and reducing adverse event rates, pharmacogenomics plays a critical role in patient stratification. Because it improves the precision and efficacy of medical interventions, it is crucial to customized medicine.


Figure 5: pharmacogenomics & personalized medicine

- Impact of pharmacogenomics on disease treatment and outcomes
- ➤ The treatment and outcome of diseases are significantly impacted by pharmacogenomics, the study of how a person's genetic makeup influences how they react to drugs.

- ➤ Pharmacogenomics allows for the customization of treatment plans according to a patient's genetic profile. Treatment options could become safer and more effective as a result of this customization.

- ➤ Pharmacogenomics testing can help doctors choose the medication that will maximize a patient's favorable response and minimize negative effects. Pharmacogenomics enables personalized medication dosage.

- ➤ By considering the patient's genetic traits, doctors can calculate the optimal dosage to produce therapeutic results without causing harm. These at-risk patients can be identified using pharmacogenomics, which can also help doctor's select safer treatment alternatives with fewer adverse effects.

- ➤ Pharmacogenomics data can be used to speed up this procedure, increasing patient satisfaction and symptom alleviation faster. This prevents the unnecessary use of useless treatments and lowers healthcare costs.

- ➤ Targeted medicines designed to address these anomalies can improve the effectiveness of cancer treatment. This information can be used by pharmaceutical companies to speed up clinical trials and the time it takes for medications to be released into the market.

- ➤ Pharmacogenomics significantly influences disease treatment and results by tailoring medicinal interventions to each patient's distinct genetic traits. This approach improves patient outcomes which also increases treatment efficacy, reduces adverse effects, and enhances healthcare overall.

- Future Directions and Innovation

- ➤ Future clinical use of pharmacogenomics is expected to lead to improvements in patient care and personalized treatment.

➢ The field is expected to undergo a number of changes and advances. Pharmacogenomic testing will be utilized more frequently as genetic testing costs come down.

➢ This may entail routine testing documented in the patient's electronic health record to guide treatment decisions.

➢ Its incorporation into Electronic Health Records (EHRs) makes it easier for medical professionals to obtain and utilize genomic data in real time while making decisions.

➢ Medical practitioners will be able to swiftly decide on a patient's treatment plan based on their genetic profile by developing point-of-care genetic testing tools that are both rapid and reasonably priced.

➢ With the use of artificial intelligence and machine learning algorithms, medical personnel will be able to evaluate complex genetic data and suggest treatments with greater accuracy and speed.

➢ The growing establishment and updating of clinical guidelines for pharmacogenomics testing and treatment decisions will provide clear recommendations for healthcare professionals.

➢ The future of pharmacogenomics in clinical practice is defined by increased accessibility, integration, and use of genetic data in treatment decisions. This tailored approach to healthcare may enhance treatment efficacy, reduce side effects, and improve patient outcomes for a range of illnesses.

CONCLUSION

✓ In summary, the use of pharmacogenomics in clinical settings is a cutting-edge approach in medicine that has enormous promise to improve patient outcomes.

✓ Pharmacogenomics plays a key role in patient stratification by enabling clinicians to categorize patients based on their genetic profiles and modify treatment plans accordingly.

✓ Precision medicine improves patient care, minimizes adverse effects, and increases therapeutic efficacy. Treatments become safer and more effective as a result, reducing the burden that illness places on patients and the healthcare system.

✓ Pharmacogenomics seems to be in a strong position to grow and develop more in the future. As the field advances, it is anticipated to

significantly transform healthcare delivery by offering patients customized, effective treatment programs that have the potential to revolutionize the medical industry.

REFERENCE

[1] Roden DM, Wilke RA, Kroemer HK, Stein CM. Pharmacogenomics: the genetics of variable drug responses. Circulation. 2011 Apr 19;123 (15):1661-70.

[2] Gupta PD. Pharmacogenetics, pharmacogenomics and ayurgenomics for personalized medicine: a paradigm shift. Indian journal of pharmaceutical sciences. 2015 Mar;77 (2):135.

[3] Guo Y, Shafer S, Weller P, Usuka J, Peltz G. Pharmacogenomics and drug development. Pirmohamed M. Pharmacogenomics: current status and future perspectives. Nature Reviews Genetics. 2023 Jun;24(6):350-62.

[4] Singh DB. The impact of pharmacogenomics in personalized medicine. Current Applications of Pharmaceutical Biotechnology. 2020:369-94.

[5] Spreafico R, Soriaga LB, Grosse J, Virgin HW, Telenti A. Advances in genomics for drug development. Genes. 2020 Aug 15;11(8):942.

[6] Guo C, Xie X, Li J, Huang L, Chen S, Li X, Yi X, Wu Q, Yang G, Zhou H, Liu JP. Pharmacogenomics guidelines: Current status and future development. Clinical and Experimental Pharmacology and Physiology. 2019 Aug;46(8):689-93.

[7] Chenoweth MJ, Giacomini KM, Pirmohamed M, Hill SL, van Schaik RH, Schwab M, Shuldiner AR, Relling MV, Tyndale RF. Global pharmacogenomics within precision medicine: challenges and opportunities. Clinical Pharmacology & Therapeutics. 2020 Jan;107(1):57-61.

[8] Shukla R. Pharmacogenomics: overview, applications, and recent developments. Drug Design-Novel Adv Omics Field Appl. 2020 Oct 12.

[9] Rollinson V, Turner R, Pirmohamed M. Pharmacogenomics for primary care: an overview. Genes. 2020 Nov 12;11(11):1337.

[10] Jhawat V, Gulia M, Gupta S, Maddiboyina B, Dutt R. Integration of pharmacogenomics and theranostics with nanotechnology as quality by

design (QbD) approach for formulation development of novel dosage forms for effective drug therapy. Journal of controlled release. 2020 Nov 10;327:500- 11.

[11] Tarasov A, Stepanov AA, Kaysheva AL. Pharmacogenetic testing: a tool for personalized drug therapy optimization. Pharmaceutics. 2020 Dec 19;12(12):1240.

[12] Elewa H, Awaisu A. Pharmacogenomics in pharmacy practice: current perspectives. Integrated Pharmacy Research and Practice. 2019 Nov 8:97-104.

[13] Garcia-Garcia I, Seco-Meseguer E, Borobia AM, Carcas-Sansuán AJ. Implementing pharmacogenetics in clinical trials: considerations about current methodological, ethical, and regulatory challenges. Expert Review of Clinical Pharmacology. 2024 Jan 2;17(1):1-0.

[14] Orrico KB. Basic concepts in genetics and pharmacogenomics for pharmacists. Drug Target Insights. 2019 Nov;13:1177392819886875.

[15] Milko LV, Chen F, Chan K, Brower AM, Agrawal PB, Beggs AH, Berg JS, Brenner SE, Holm IA, Koenig BA, Parad RB. FDA oversight of NSIGHT genomic research: the need for an integrated systems approach to regulation. NPJ genomic medicine. 2019 Dec 10;4(1):32.

[16] Abdullah-Koolmees H, Van Keulen AM, Nijenhuis M, Deneer VH. Pharmacogenetics guidelines: overview and comparison of the DPWG, CPIC, CPNDS, and RNPGx guidelines. Frontiers in pharmacology. 2021 Jan 25;11:595219.